about
Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cellsChromatin deregulation in disease.Crosstalk among the proteome, lysine phosphorylation, and acetylation in romidepsin-treated colon cancer cells.Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma.AP-1 confers resistance to anti-cancer therapy by activating XIAP.
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Romidepsin for the treatment of non-Hodgkin's lymphoma.
@en
type
label
Romidepsin for the treatment of non-Hodgkin's lymphoma.
@en
prefLabel
Romidepsin for the treatment of non-Hodgkin's lymphoma.
@en
P2860
P1476
Romidepsin for the treatment of non-Hodgkin's lymphoma.
@en
P2093
Steven Grant
Victor Y Yazbeck
P2860
P304
P356
10.1517/13543784.2015.1041586
P407
P577
2015-05-04T00:00:00Z